產(chǎn)品優(yōu)勢：

（1）無血清、無需滋養(yǎng)層細(xì)胞；可收集無外源干擾的純凈外泌體；

（2）可應(yīng)用于iPSC工業(yè)化2D和3D大規(guī)模培養(yǎng)和擴(kuò)增；

（3）自主化、國產(chǎn)化的原研體系；供貨穩(wěn)定，高性價(jià)比；

（4）支持臨床級/藥品級細(xì)胞培養(yǎng)，培養(yǎng)的iPSC細(xì)胞通過了中國食品藥品檢定研究院質(zhì)量復(fù)核；iPSC來源功能藥物通過了IND默示許可。

產(chǎn)品規(guī)格

 將基礎(chǔ)液和添加物混勻配置成完全培養(yǎng)基，可在2℃～8℃中存儲(chǔ)，2周內(nèi)用完。

細(xì)胞形態(tài)及功能鑒定

A、B、C：連續(xù)培養(yǎng)的hiPSC細(xì)胞株細(xì)胞形態(tài)圖示。標(biāo)尺：200μm。

D：細(xì)胞表面標(biāo)志物檢測：SSEA4+，Tra-1-81+。E：細(xì)胞多能基因檢測：OCT4+，NANOG+。

F：連續(xù)培養(yǎng)的hiPSC（P30）細(xì)胞核型檢測：46，XX。

文獻(xiàn)引用

Base editing-mediated splicing correction therapy for spinal muscular atrophy

2020. Xiang Lin, et al. Cell Research(IF 46.297).

Disruption of splicing-regulatory elements using CRISPR/Cas9 to rescue spinal muscular atrophy in human iPSCs and mice

2019.Jinjing Li，et al.National Science Review(IF 23.178).

Inducible Pluripotent Stem Cel-Derived Sma Extracelular Vesicles Reuvenate Senescent lood-Brain Barrier to Protect against ischemic Stroke in Aged .

2022. Qing Li, et al. ACS Nano(IF 18.0280).

ESC-sEVs Rejuvenate Senescent Hippocampal NSCs by Activating Lysosomes to Improve Cognitive Dysfunction in Vascular Dementia

2020. Guowen Hu, et al. Advanced Science(IF 17.521).

Human ESC-sEVs alleviate age-related bone loss by rejuvenating senescent bone marrow-derived mesenchymal stem cells

2020. Liangzhi Gong, et al. Journal of Extracellular Vesicles(IF 17.3378).

ESC-SEVs Reiuvenate Aging Hippocampal NSCs by Transferring SMADs to Regulate the MYT1-Eqln3-Sirt1 Axis

2021. Guowen Hu. Molecular Therapy (IF 12.9101)

更多文獻(xiàn)引用，請撥打021-61283010詳細(xì)咨詢